335417-94-2

Upstream product

• 2916-68-9 2-(Trimethylsilyl)ethanol 
• 335417-13-5 (3R,4R,5S)-4-(acetylamino)-5-allyl-3-isopropoxy-1-cyclohexene-1-carboxylic acid 
• 105539-78-4 (1R,3S,4S,5R)-3-bromo-1-hydroxy-7-oxo-6-oxabicyclo[3.2.1]oct-4-yl benzoate 
• 335417-45-3 methyl (1S,5S,6R)-5-allyl-7-azabicyclo[4.1.0]hept-2-ene-3-carboxylate 
• 335417-32-8 (1R,2R,3S,5S)-3-allyl-5-(methoxycarbonyl)-2,5-bis[(methylsulfonyl)oxy]cyclohexyl benzoate 
• 335417-48-6 methyl (1S,5S,6R)-5-allyl-7-trityl-7-azabicyclo[4.1.0]hept-2-ene-3-carboxylate 
• 335417-29-3 (1R,2R,3S,5S)-3-allyl-2-hydroxy-5-(methoxycarbonyl)-5-[(methylsulfonyl)oxy]cyclohexyl benzoate 
• 335417-22-6 (1S,3S,4R,5R)-3-allyl-1-[(methylsulfonyl)oxy]-7-oxo-6-oxabicyclo[3.2.1]oct-4-yl benzoate 
• 335417-35-1 methyl (1S,3S,4R,5R)-3-allyl-5-hydroxy-1,4-bis[(methylsulfonyl)oxy]cyclohexanecarboxylate 
• 335417-26-0 methyl (1S,3S,4R,5R)-3-allyl-4,5-dihydroxy-1-[(methylsulfonyl)oxy]cyclohexanecarboxylate 
• 335417-50-0 methyl (3R,4R,5S)-4-(acetylamino)-5-allyl-3-isopropoxy-1-cyclohexene-1-carboxylate 
• 335417-43-1 methyl (3S,4S,5S)-5-allyl-3-azido-4-[(methylsulfonyl)oxy]-1-cyclohexene-1-carboxylate 
• 335417-41-9 methyl (3S,4S,5S)-5-allyl-3-azido-4-hydroxy-1-cyclohexene-1-carboxylate 
• 335417-38-4 methyl (1R,5S,6S)-5-allyl-7-oxabicyclo[4.1.0]hept-2-ene-3-carboxylate 

Downstream Products

• 335418-01-4 (3R,4R,5R)-4-Acetylamino-3-isopropoxy-5-methoxycarbonylmethyl-cyclohex-1-enecarboxylic acid 2-trimethylsilanyl-ethyl ester 
• 335417-98-6 2-(trimethylsilyl)ethyl (3R,4R,5R)-4-(acetylamino)-3-isopropoxy-5-(2-oxoethyl)-1-cyclohexene-1-carboxylate 
• 335417-96-4 2-(trimethylsilyl)ethyl (3R,4R,5R)-4-(acetylamino)-5-(2,3-dihydroxypropyl)-3-isopropoxy-1-cyclohexene-1-carboxylate 

Relevant academic research and scientific papers

Neuraminidase inhibitors

The present invention provides compounds of formula Ia and Ib or a pharmaceutically acceptable salt, prodrug, or ester thereof, useful in the inhibition of neuraminidase enzymes from disease-causing microorganisms, especially influenza neuraminidase, phar

Design, synthesis, and neuraminidase inhibitory activity of GS-4071 analogues that utilize a novel hydrophobic paradigm.

Structure-based design has led to the synthesis of a novel analogue of GS-4071, an influenza neuraminidase inhibitor, in which the basic amino group has been replaced by a hydrophobic vinyl group. An X-ray co-crystal structure of the new inhibitor (K(i)=4